SG10201806472SA - A Pharmaceutical Composition for Prevention of Diet Induced Obesity - Google Patents

A Pharmaceutical Composition for Prevention of Diet Induced Obesity

Info

Publication number
SG10201806472SA
SG10201806472SA SG10201806472SA SG10201806472SA SG10201806472SA SG 10201806472S A SG10201806472S A SG 10201806472SA SG 10201806472S A SG10201806472S A SG 10201806472SA SG 10201806472S A SG10201806472S A SG 10201806472SA SG 10201806472S A SG10201806472S A SG 10201806472SA
Authority
SG
Singapore
Prior art keywords
prevention
pharmaceutical composition
diet induced
obesity
induced obesity
Prior art date
Application number
SG10201806472SA
Inventor
Ankit Shyam Singh
Vedprakash Mishra
Neelima Tongra
Original Assignee
Frimline Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frimline Private Ltd filed Critical Frimline Private Ltd
Publication of SG10201806472SA publication Critical patent/SG10201806472SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

A PHARMACEUTICAL COMPOSITION FOR PREVENTION OF DIET INDUCED OBESITY 5 The present invention relates to a pharmaceutical composition/formulation for the prevention of diet induced obesity. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Oleoylethanolamide (OEA) and other natural ingre- dients can be used for treatment of obesity and its related disorders associated with fat me- tabolism like non-alcoholic steatohepatitis (NASH) , non-alcoholic fatty liver disease 10 (NAFLD) . This can also be helpful in controlling obesity by way of maintaining body weight. The invention also provides various formulations and methods of preparing the same. [Figure 1] 15
SG10201806472SA 2017-08-19 2018-07-30 A Pharmaceutical Composition for Prevention of Diet Induced Obesity SG10201806472SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721029447 2017-08-19

Publications (1)

Publication Number Publication Date
SG10201806472SA true SG10201806472SA (en) 2019-03-28

Family

ID=63244444

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201806472SA SG10201806472SA (en) 2017-08-19 2018-07-30 A Pharmaceutical Composition for Prevention of Diet Induced Obesity

Country Status (19)

Country Link
US (1) US10702487B2 (en)
EP (1) EP3443987B1 (en)
BR (1) BR102018016746A8 (en)
CA (1) CA3012675C (en)
CY (1) CY1124010T1 (en)
DK (1) DK3443987T3 (en)
EA (1) EA201891651A3 (en)
ES (1) ES2864136T3 (en)
HR (1) HRP20210466T1 (en)
HU (1) HUE053678T2 (en)
LT (1) LT3443987T (en)
MY (1) MY177974A (en)
PH (1) PH12018000207B1 (en)
PL (1) PL3443987T3 (en)
PT (1) PT3443987T (en)
RS (1) RS61628B1 (en)
SG (1) SG10201806472SA (en)
SI (1) SI3443987T1 (en)
UA (1) UA122710C2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041495A2 (en) * 2019-08-26 2021-03-04 The Trustees Of Indiana University Method to maintain or enhance tissue
CN111084301B (en) * 2019-12-30 2023-08-22 内江师范学院 Mulberry leaf extract fish feed adhesive and preparation method and application thereof
CN113712206A (en) * 2021-09-16 2021-11-30 湖南希尔天然药业有限公司 A composition containing folium Mori DNJ and folium Mori peptide and its preparation method
WO2023114722A1 (en) * 2021-12-13 2023-06-22 The Regents Of The University Of California Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide
WO2023250211A2 (en) * 2022-06-24 2023-12-28 Veroscience Llc Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042687A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of treating obesity by the oral administration of a predigested protein composition
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
AU2003296895A1 (en) 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
WO2004045307A2 (en) 2002-11-18 2004-06-03 Natural Asa Dietry supplements and foods product comprising oleylethanolamide
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EP1677780A4 (en) 2003-10-16 2007-05-02 Univ California Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
EP1917007A2 (en) 2005-07-14 2008-05-07 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
JP5388602B2 (en) * 2008-01-25 2014-01-15 小林製薬株式会社 Pharmaceutical composition for anti-obesity
CN102036559A (en) 2008-05-19 2011-04-27 雀巢产品技术援助有限公司 Methods for reducing lipid absorption by an animal
CA2843265C (en) 2010-07-28 2019-09-17 The Regents Of The University Of California Peripherally restricted faah inhibitors
WO2012090225A2 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
MX2013013098A (en) 2011-05-10 2013-12-16 Nestec Sa Methods and compositions for promoting lean body mass growth.
EP2744778B1 (en) 2011-08-19 2019-01-16 The Regents of The University of California Meta-substituted biphenyl peripherally restricted faah inhibitors
CN102579414A (en) 2012-01-29 2012-07-18 厦门大学 Application of oleoylethanolamide being used as drug for reducing blood fat and preventing nonalcoholic fatty liver disease
KR102137714B1 (en) 2012-07-24 2020-07-27 바이알 - 포르텔라 앤드 씨에이 에스에이 Urea compounds and their use as enzyme inhibitors
EP2892366A1 (en) 2012-09-07 2015-07-15 Nestec S.A. Oleoylethanolamide compositions
ITMI20131180A1 (en) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-ALCHIL TRIAZOLYL CARBAMMATES AS INHIBITORS OF HYDROLASIS OF AMIDIDES OF FATTY ACIDS (FAAH)
EP3022179B1 (en) 2013-07-18 2017-11-15 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
RS56297B1 (en) 2013-07-24 2017-12-29 BIAL PORTELA & Cª S A Imidazolecarboxamides and their use as faah inhibitors
JP2016528227A (en) 2013-08-01 2016-09-15 ビアル−ポルテラ エ コンパニア，ソシエダッド アノニマ Urea compounds and their use as enzyme inhibitors
ES2908240T3 (en) 2014-04-07 2022-04-28 Univ California Fatty acid amide hydrolase (FAAH) enzyme inhibitors with improved oral bioavailability and their use as medicaments
AU2016263292B2 (en) 2015-05-21 2021-04-01 Scisparc Ltd Combinations of opioids and N-acylethanolamines
RU2737893C2 (en) 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Pegylated lipid nanoparticle with a bioactive lipophilic compound

Also Published As

Publication number Publication date
PL3443987T3 (en) 2021-08-02
EA201891651A3 (en) 2019-05-31
HUE053678T2 (en) 2021-07-28
UA122710C2 (en) 2020-12-28
MY177974A (en) 2020-09-28
BR102018016746A2 (en) 2019-03-26
EP3443987A1 (en) 2019-02-20
BR102018016746A8 (en) 2023-02-14
RS61628B1 (en) 2021-04-29
ES2864136T3 (en) 2021-10-13
DK3443987T3 (en) 2021-03-22
PH12018000207A1 (en) 2019-06-03
US20190054046A1 (en) 2019-02-21
EA201891651A2 (en) 2019-02-28
CY1124010T1 (en) 2022-05-27
CA3012675C (en) 2021-06-15
PH12018000207B1 (en) 2019-06-03
PT3443987T (en) 2021-03-18
HRP20210466T1 (en) 2021-05-14
LT3443987T (en) 2021-04-26
CA3012675A1 (en) 2019-02-19
EP3443987B1 (en) 2020-12-23
US10702487B2 (en) 2020-07-07
SI3443987T1 (en) 2021-07-30

Similar Documents

Publication Publication Date Title
SG10201806472SA (en) A Pharmaceutical Composition for Prevention of Diet Induced Obesity
EP2636404A3 (en) Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
PH12018502634A1 (en) Topical compositions of apremilast
MY151018A (en) Use of nutritional compositions for preventing disorders
MY176679A (en) Use of nutritional compositions for preventing disorders
SG10201807815WA (en) Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism
BRPI0608877B8 (en) liquid rotavirus immunogenic composition, use of a rotavirus antigen, a sugar and a carboxylate, and, method for preparing a liquid rotavirus composition
JOP20190147A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2019012884A (en) Combination therapy.
EA033540B1 (en) Composition comprising okra for use in reducing dietary fat absorption
WO2018093238A3 (en) Composition comprising as active ingredient strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity
MX2017006639A (en) Methods and compositions for preserving lean body mass and promoting fat loss during weight loss.
BRPI0811347A2 (en) "medicinal herbaceous extract with anti-obesity effect"
MX2021002902A (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient.
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
ZA202103209B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
MY190709A (en) A polypeptide from mormodica charantia for use for the regulation of genes related to inflammation, lipid and glucose metabolism
SG11201808241WA (en) Composition for skin moisturization or skin whitening, containing pentacyclic triterpene caffeic acid esters
MX2021005669A (en) Methods for enhancing metabolic health in an animal.
GB202000317D0 (en) The herbal formulation for treating non-alcoholic fatty diseases and non-alcohlic steatoHepatitis
ZA202300838B (en) Formulations